Form 4: Director Raman Boosts BDTX Stake with Stock Compensation

Black Diamond Therapeutics Director Prakash Raman acquired 6,105 shares of common stock in lieu of cash compensation for his annual services.

Summary

• Prakash Raman, a Director at Black Diamond Therapeutics, Inc. (BDTX), acquired 6,105 shares of common stock.
• The transaction occurred on March 20, 2026, and the shares were valued at $2.15 each, based on the closing market price on March 19, 2026.
• These shares were issued as compensation for annual services as a non-employee director, in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• Raman elected to receive shares of common stock instead of cash compensation.
• Following this transaction, Prakash Raman beneficially owns a total of 37,132 shares of Black Diamond Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event. While a routine compensation, a director choosing stock over cash indicates a degree of confidence in the company's future and aligns their interests with shareholders.

Positives

• A director electing to receive stock instead of cash compensation can signal confidence in the company's future performance and aligns their interests more closely with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as directors receiving stock compensation, are routinely disclosed via Form 4 filings. While this specific transaction is a standard compensation event, it generally reflects a director's continued alignment with the company's equity performance, a common practice in the biotechnology sector to conserve cash and incentivize long-term value creation.

Related Party Transactions

• The acquisition of 6,105 shares by Director Prakash Raman constitutes a related party transaction, as it is compensation provided to a non-employee director under the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The transaction demonstrates continued alignment of a director's interests with shareholders through equity ownership, potentially signaling confidence in the company's long-term prospects.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine compensation event where a director received stock in lieu of cash. While it shows continued alignment, it does not present new material information that would significantly alter the investment thesis for Black Diamond Therapeutics. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

BDTX, Black Diamond Therapeutics, Prakash Raman, Form 4, insider transaction, director compensation, stock acquisition, equity compensation